Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 10/20 | 0.41 |
| ▸ | PER2 | O15055 | 4/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 4/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282097 | 1.00 | HTR3A (0.41) | HTR3APER2CRY1CRY2TP53 | |
| SCHEMBL6285611 | 0.87 | HTR6 (0.42) | SMN1; SMN2TPSAB1 | |
| SCHEMBL6285605 | 0.87 | HTR6 (0.42) | SMN1; SMN2TPSAB1 | |
| SCHEMBL6285344 | 0.86 | PTGDR2 (0.35) | HTR3A | |
| SCHEMBL6285340 | 0.86 | PTGDR2 (0.35) | HTR3A | |
| SCHEMBL6282971 | 0.85 | HTR3A (0.47) | HTR3ASMN1; SMN2TPSAB1 | |
| SCHEMBL6282976 | 0.85 | HTR3A (0.47) | HTR3ASMN1; SMN2TPSAB1 | |
| SCHEMBL6282001 | 0.85 | HTR6 (0.42) | — | |
| SCHEMBL6281998 | 0.85 | HTR6 (0.42) | — | |
| SCHEMBL6286951 | 0.84 | HTR3A (0.38) | HTR3APER2CRY1CRY2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906095-B2 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2A | HTR3A 11/4885PER2 1550/4885CRY1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.